Abstract
Twenty-five women presenting moderate-severe PCOS-dependant hirsuitism were treated for 6 months with GnRH-A (Group A) or pill-combined and GnRH (Group B). Both therapeutic regimens significantly decreased androgen plasma levels. Hair diameter reduced in Group A by 22-34% and in Group B by 25-35%, while hirsuitism score respectively decreased by 22 and 24%. Clinical results, overlapping in the two groups, prove that GnRH-A are active in hirsuitism. Side effects, however, especially a decreased bone density (3.9%) in Group A make it necessary an association with oral contraceptive.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Androgens / blood
-
Bone Density / drug effects
-
Contraceptives, Oral, Combined / administration & dosage
-
Cyproterone Acetate / administration & dosage
-
Ethinyl Estradiol / administration & dosage
-
Female
-
Follicle Stimulating Hormone / blood
-
Hair / growth & development
-
Hirsutism / blood
-
Hirsutism / drug therapy*
-
Hirsutism / etiology
-
Humans
-
Leuprolide / adverse effects
-
Leuprolide / pharmacology
-
Leuprolide / therapeutic use*
-
Luteinizing Hormone / blood
-
Polycystic Ovary Syndrome / complications
-
Prolactin / blood
-
Severity of Illness Index
-
Sex Hormone-Binding Globulin / analysis
Substances
-
Androgens
-
Contraceptives, Oral, Combined
-
Sex Hormone-Binding Globulin
-
Ethinyl Estradiol
-
Cyproterone Acetate
-
Prolactin
-
Luteinizing Hormone
-
Follicle Stimulating Hormone
-
Leuprolide